PE20091436A1 - Derivados de sulfonamidas sustituidas como moduladores b1r - Google Patents

Derivados de sulfonamidas sustituidas como moduladores b1r

Info

Publication number
PE20091436A1
PE20091436A1 PE2009000060A PE2009000060A PE20091436A1 PE 20091436 A1 PE20091436 A1 PE 20091436A1 PE 2009000060 A PE2009000060 A PE 2009000060A PE 2009000060 A PE2009000060 A PE 2009000060A PE 20091436 A1 PE20091436 A1 PE 20091436A1
Authority
PE
Peru
Prior art keywords
modulators
sulfonamid
methoxy
aryl
halogen
Prior art date
Application number
PE2009000060A
Other languages
English (en)
Inventor
Beatrix Merla
Stefan Oberboersch
Ruth Jostock
Michael Engels
Stefan Schunk
Melanie Reich
Sabine Hees
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20091436A1 publication Critical patent/PE20091436A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE SULFONAMIDA DE FORMULA (I), DONDE m Y n SON UN ENTERO DE 0 A 2; p ES 1 O 2; Q ES UN ATOMO DE OXIGENO O CH2; X ES N O CR5; Y ES N O CR6; Z ES N O CR7; R1 ES ARILO O HETEROARILO; R2 Y R3 SON H, ALQUILO C1-C6, ARILO, ENTRE OTROS; R4 ES H, HALOGENO, CN, NO2, ENTRE OTROS; R5, R6 Y R7 SON H, HALOGENO, ALQUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-(2-(2-(6-((DIMETILAMINO)METIL)-1-FENILO-3,4-DIHIDROPIRROLO[1,2-a]PIRAZIN-2(1H)-IL)-2-OXOETOXI)ETIL)-4-METOXI-N,2,3,6-TETRAMETILBENZENOSULFONAMIDA, 4-METOXI-N,2,6-TRIMETIL-N-(2-(2-OXO-2-(2-(PIPERIDIN-1-ILMETIL)-5,6-DIHIDROIMIDAZOL[1,2-a]PIPERAZIN-7(8H)-IL)ETOXI)ETIL)BENZENOSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES 1 DE BRADICININA (B1R) Y SON UTILES EN EL TRATAMIENTO DEL DOLOR EN PARTICULAR DOLOR AGUDO, NEUROPATICO E INFLAMATORIO, ENTRE OTRAS
PE2009000060A 2008-01-17 2009-01-16 Derivados de sulfonamidas sustituidas como moduladores b1r PE20091436A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08000840 2008-01-17

Publications (1)

Publication Number Publication Date
PE20091436A1 true PE20091436A1 (es) 2009-10-08

Family

ID=39539534

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000060A PE20091436A1 (es) 2008-01-17 2009-01-16 Derivados de sulfonamidas sustituidas como moduladores b1r

Country Status (8)

Country Link
US (1) US8263598B2 (es)
EP (1) EP2229395A1 (es)
JP (1) JP2011509961A (es)
AR (1) AR070187A1 (es)
CA (1) CA2712265A1 (es)
CL (1) CL2009000085A1 (es)
PE (1) PE20091436A1 (es)
WO (1) WO2009090054A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI357902B (en) * 2005-04-01 2012-02-11 Lg Life Science Ltd Dipeptidyl peptidase-iv inhibiting compounds, meth
TW200944530A (en) * 2008-04-09 2009-11-01 Gruenenthal Chemie Substituted sulfonamide derivatives
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN102464661B (zh) * 2010-11-16 2015-04-01 天津药明康德新药开发有限公司 一种5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸乙酯的制备方法
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
CN102229610B (zh) * 2011-04-22 2014-10-29 中山大学 一种光学纯手性1,2,3,4-四氢吡咯并[1,2-a]吡嗪化合物的合成方法
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
CN103113324B (zh) * 2013-02-07 2015-08-05 浙江工业大学 一种n-磺酰基取代的四氢吡咯类化合物的制备方法
CA3005353A1 (en) 2015-11-20 2017-05-26 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
KR102495650B1 (ko) * 2017-04-12 2023-02-02 에프. 호프만-라 로슈 아게 알데히드 함유 표적 분자의 라벨링 방법
CN109956865B (zh) * 2017-12-22 2022-09-13 浙江瑞博制药有限公司 一种西格列汀中间体的制备方法
CN114891004B (zh) * 2017-12-23 2024-01-05 浙江九洲药业股份有限公司 一种西格列汀中间体化合物的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE523926C2 (sv) * 1999-06-15 2004-06-01 Hans Lundqvist Stentarrangemang
DE602004021358D1 (de) * 2003-03-25 2009-07-16 Fournier Lab Sa Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen
WO2004103276A2 (en) * 2003-05-14 2004-12-02 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2007101007A2 (en) 2006-02-23 2007-09-07 Neurogen Corporation Aryl sulfonyl heterocycles
EP2086935A1 (de) * 2006-10-16 2009-08-12 Grünenthal GmbH Substituierte sulfonamid-derivate als bradykinin 1 rezeptor modulatoren

Also Published As

Publication number Publication date
US20090186899A1 (en) 2009-07-23
AR070187A1 (es) 2010-03-17
CL2009000085A1 (es) 2009-03-20
CA2712265A1 (en) 2009-07-23
WO2009090054A1 (en) 2009-07-23
US8263598B2 (en) 2012-09-11
EP2229395A1 (en) 2010-09-22
JP2011509961A (ja) 2011-03-31

Similar Documents

Publication Publication Date Title
PE20091436A1 (es) Derivados de sulfonamidas sustituidas como moduladores b1r
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ATE493404T1 (de) Azabicyclo-(3,1,0)-hexan-derivate als modulatoren von dopamin-d3-rezeptoren
PE20091819A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-HETEROARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLIACION EN TERAPEUTICA
PE20080671A1 (es) DERIVADOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a]PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20140390A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
BR112014027143A2 (pt) pirrolobenzodiazepinas
PE20091403A1 (es) Derivados de carboxamidas n-azabiciclicas y su preparacion
EA200870196A1 (ru) Индолсульфонамидные модуляторы рецепторов прогестерона
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
PE20070172A1 (es) DERIVADOS BICICLICOS COMO INHIBIDORES DE p38
CO6561821A2 (es) Compuesto n-(1h-indazol-4-il)imidazol[1.2-a]piridin -3-carboxamida sustituidos como inhibidores de cfms
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
PE20120534A1 (es) PIRIMIDINAS FUSIONADAS COMO INHIBIDORES DE Akt
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
ATE484502T1 (de) Neue verbindungen
RS53903B1 (en) ETHINYL DERIVATIVES AS POSITIVE MGLUR5 MODULATORS
ATE455113T1 (de) 3-triazolylthioalkyl-3-azabicyclo ä3.1.0ühexane und ihre verwendung als liganden des dopamin-d3- rezeptors
UY29204A1 (es) Compuestos de imidazo(1,2-a)piridina, composiciones, usos y métodos relacionados
PE20091350A1 (es) Derivados de sulfonamidas sustituidas
MY170822A (en) Ethynyl derivatives as mglur5 allosteric modulators
MA32192B1 (fr) Composés dérivés d'azétidines, leur préparation et leur application en thérapeutique
PE20081703A1 (es) Nuevos derivados triciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed